ReviewFrontiers in cardiovascular medicine2021
Transcatheter Mitral Valve Replacement and Thrombosis: A Review.
Review in Frontiers in cardiovascular medicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed.
- Transcatheter Mitral Valve Replacement: Clinical Challenges, Evolving Indications, and Future Directions.Structural heart : the journal of the Heart Team · 2026Review
- TENDYNE mitral valve implantation complicated by heparin-induced thrombocytopenia in a patient with NSCLC: a case report.European heart journal. Case reports · 2026Article
- Management of Bioprosthetic Valve Thrombosis Following Transcatheter Mitral Valve Replacement.JACC. Case reports · 2026Article
- Transcatheter Mitral Valve Replacement in Failed Mitral Bioprosthesis: Case Report.Case reports in cardiology · 2026Article
- Review
- Massive Superinfected Thrombosis of Dual-Frame Transcatheter Mitral Valve Replacement.JACC. Case reports · 2024Article
- Emergent Surgical Replacement of a Tendyne Prosthesis for Bioprosthetic Valve Thrombosis.JACC. Case reports · 2024Article
- Review
- Looking towards the future: patient-specific computational modeling to optimize outcomes for transcatheter mitral valve repair.Frontiers in cardiovascular medicine · 2023Review
- Transcatheter Mitral Valve-in-Valve Implantation with the Balloon-Expandable Myval Device.Journal of clinical medicine · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Mitral regurgitation is the most prevalent form of moderate or severe valve disease in developed countries. Surgery represents the standard of care for symptomatic patients with severe mitral regurgitation, but up to 50% of patients are denied surgery because of high surgical risk. In this context, different transcatheter options have been developed to address this unmet need. Transcatheter mitral valve replacement (TMVR) is an emergent field representing an alternative option in high complex contexts when transcatheter mitral valve repair is not feasible or suboptimal due to anatomical issues. However, TMVR is burdened by some device-specific issues (device malposition, migration or embolization, left ventricular outflow tract obstruction, hemolysis, thrombosis, stroke). Here we discuss the thrombotic risk of TMVR and current evidence about anticoagulation therapy after TMVR.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.